Experimental Skin Cancer Vaccine Shows Promising Results in Trial
An experimental vaccine targeting melanoma has significantly reduced the risk of the cancer returning or spreading in a late-stage clinical trial conducted by Merck and Moderna. This study marks the first positive Phase 3 trial of an mRNA-based personalized cancer therapy.
Trial Details
The study, known as INTerpath-001, involved 1,137 global patients who had undergone surgery for high-risk melanoma (Stages IIB through IV). Participants received either a combination of Keytruda and the personalized vaccine or Keytruda with a placebo. The results showed that those receiving the vaccine combination had better recurrence-free survival, meaning their cancer was less likely to return compared to those receiving Keytruda alone. Additionally, the vaccine improved distant metastasis-free survival, indicating the cancer was less likely to spread to distant parts of the body.
How the Vaccine Works
The personalized mRNA vaccine, intismeran autogene, differs from traditional vaccines, as it is administered after surgery to help the body target remaining cancer cells. Tumor and healthy cells are sampled post-surgery, and advanced algorithms analyze the genetic sequence to select up to 34 tumor-specific neoantigens encoded into the treatment.
Dr. Murad Alam noted that melanomas vary between patients, making traditional chemotherapy less effective in some cases. The modified approach directs the immune system to specific tumor targets, enhancing effectiveness while sparing normal cells.
AI’s Role in Treatment
Artificial intelligence plays a crucial role in determining which antigens to include in the vaccine, making the process feasible for individual patients. This technology optimizes precision and resource efficiency, highlighting the future potential for similar vaccines.
Future Plans
Merck and Moderna plan to discuss potential regulatory filings with authorities globally. Further studies will explore this vaccine technology in treating other cancers like lung, bladder, and kidney cancers. Although early findings are promising, the study did not conclusively show how long patients remain cancer-free or if they live longer. Effects were based on investigator assessments rather than independent reviews, and the study focused solely on specific melanoma stages post-surgery, limiting the applicability to other cancers.
No new safety concerns were identified, and side effects were mild, including fatigue, chills, and pain at the injection site. Dr. Alam emphasized the benefits of this targeted therapy, as it avoids the severe side effects common with traditional cancer medications.